Expert review of anticancer therapy · 2025
Chemotherapy-induced neutropenia as a prognostic factor in pancreatic cancer: a systematic review and meta-analysis.
Систематический обзорСтатьяМетаанализНазвание и аннотация: Перевод пока не подготовлен
Обработка статьи · этапы, ошибки и управление
Загрузка состояния…
Ошибки и ограничения
История · было → стало
Состояние обновляется каждые 5 секунд, пока блок открыт. Процент показывается только там, где известен объём работы. Пауза останавливает продолжение этапа; текущий запрос к источнику может завершиться.
de Oliveira Diogo Patrick Nogueira, Doro Lerco Amandha, Duenha Garanhani Anna, de Tarso Coelho Jardim Paulo, José Grande Antônio, Reche Razente Gustavo
Аннотация
BACKGROUND: Chemotherapy-induced neutropenia (CIN) may reflect higher pharmacodynamic exposure and relate to improved outcomes, but its clinical relevance in pancreatic cancer remains uncertain.
METHODS: PROSPERO-registered, PRISMA-compliant systematic review and meta-analysis. PubMed, Embase, and CENTRAL were searched to 18 August 2025. Eligible studies compared OS in CIN ≥G3 vs <G3. Quantitative synthesis was limited to advanced/unresectable/metastatic disease. Log(HR) and SEs were pooled with random effects (DerSimonian - Laird); heterogeneity by Q and I^2. Sensitivity analyses included 95% prediction interval, Hartung - Knapp - Sidik - Jonkman, and leave-one-out. Publication bias was not assessed (k = 5).
RESULTS: Eight observational studies met inclusion; five (all advanced disease) were meta-analyzed. CIN ≥G3 was associated with better OS (grouped HR 0.50; 95% CI 0.40-0.62; I2 = 0%), with consistent direction across studies. Sensitivity analyses confirmed robustness. ROBINS-I rated four studies at serious and four at moderate risk of bias; GRADE certainty for the pooled OS effect was moderate.
CONCLUSIONS: In advanced pancreatic cancer, CIN ≥G3 is associated with improved OS, supporting its role as a cohort-level prognostic/pharmacodynamic marker. Generalizability is limited by predominantly Japanese cohorts. Prospective multicenter studies with time-dependent modeling and control of relative dose intensity.
REGISTRATION: www.crd.york.ac.uk/prospero, identifier CRD420251005347.
METHODS: PROSPERO-registered, PRISMA-compliant systematic review and meta-analysis. PubMed, Embase, and CENTRAL were searched to 18 August 2025. Eligible studies compared OS in CIN ≥G3 vs <G3. Quantitative synthesis was limited to advanced/unresectable/metastatic disease. Log(HR) and SEs were pooled with random effects (DerSimonian - Laird); heterogeneity by Q and I^2. Sensitivity analyses included 95% prediction interval, Hartung - Knapp - Sidik - Jonkman, and leave-one-out. Publication bias was not assessed (k = 5).
RESULTS: Eight observational studies met inclusion; five (all advanced disease) were meta-analyzed. CIN ≥G3 was associated with better OS (grouped HR 0.50; 95% CI 0.40-0.62; I2 = 0%), with consistent direction across studies. Sensitivity analyses confirmed robustness. ROBINS-I rated four studies at serious and four at moderate risk of bias; GRADE certainty for the pooled OS effect was moderate.
CONCLUSIONS: In advanced pancreatic cancer, CIN ≥G3 is associated with improved OS, supporting its role as a cohort-level prognostic/pharmacodynamic marker. Generalizability is limited by predominantly Japanese cohorts. Prospective multicenter studies with time-dependent modeling and control of relative dose intensity.
REGISTRATION: www.crd.york.ac.uk/prospero, identifier CRD420251005347.